Page 15 - Biocon Biologics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Siddharth Mittal: The formulations business been a growth driver

However, we have seen weakness in our active pharmaceutical ingredients business.

Andhra pradeshSiddharth mittalBiocon biologicsEli lilly mounjaroSohini dasNovo nordiskBusiness standardBusiness newsUsiness news indiaNdia business newsNdian economy newsNdian financial news

Jefferies downgrades Biocon to underperform , sees 11% downside; here s why

Jefferies has downgraded the pharma stock Biocon to underperform from hold . However, Jefferies has maintained its target price of ₹250 for the stock, implying an 11 percent downside from its current market price of ₹281.50.

Biocon biologicsEconomic timesBiocon stockBiocon share priceBiocon sharesBiocon stock priceJefferies on bioconJefferies downgrades bioconBiocon target priceBiocon downgradeStock marketsMarket newsStock newsBusiness newsBiocon news

Biocon included in S&P Global Sustainability Yearbook 2024

Biocon included in S&P Global Sustainability Yearbook 2024
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Kiran mazumdar shawBiocon biologicsBiocon groupBiocon limited onBiocon limitedSustainability yearbookBiocon biologics limitedPatient equityPeople equityEnvironmental equityStakeholder equitySocial equityMazumdar shawDow jones sustainability indicesDow jones sustainability emergingEmerging markets

Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances

/PRNewswire/ The "Biosimilar Monoclonal Antibodies Global Market Report 2024" has been added to ResearchAndMarkets.com s offering. The expansion of the.

United statesLaura woodCoherus biosciencesMabpharm limitiedAprogen biologicsReliance life sciencesXentria incQilu pharmaceutical coOffice hours callE st office hours callReddy laboratories ltdCelltrion incLazuline biotech privateChiatai tianqing pharmaceutical group coGenor biopharma coEpygen biotech pvt ltd

We will continue to deepen our presence in segments like diabetes through product portfolio expansion: Krishnakumar Vaidyanathan, Executive Director, Eris Lifesciences

We will continue to deepen our presence in segments like diabetes through product portfolio expansion: Krishnakumar Vaidyanathan, Executive Director, Eris Lifesciences
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Krishnakumar vaidyanathanBiocon biologicsWorld health organizationEris lifesciences ltdSouth east asia regionIndian pharmaceutical marketEris lifesciencesFinancial expressExecutive directorChief operating officerEstablished therapiesEmerging therapiesChronic kidney disease